Review the findings. Check the evidence. Decide what to discuss or measure next.
MEMBER Sample 001EDITION 1.2RECORDS 22 / 6 workspacesCONTEXT REVIEWED 29 Oct 2026
Every assigned result, quality metric and review event is invented. No person was sequenced. Sources support the explanations, not these sample results or Whole DNA’s clinical performance. This is an educational product demonstration.
Executive brief
A suggested reading order, not a medical priority score
No matching findings. Clear the search or try another term.
Everyday life
FICTIONAL DATA
Use these assigned trait signals to prepare specific observations and questions. They do not replace current measurements or a clinical assessment.
E01
Food / caffeine
Higher sensitivity signal
The fictional profile is assigned a higher caffeine-sensitivity signal. Timing, sleep, symptoms and medicines still matter more than a simple “fast” or “slow” label.
Next questionWould moving my last caffeinated drink earlier change my sleep?
Exploratory associationEvidence & limits
This is an invented trait assignment, not a validated score or a personal caffeine limit. The FDA source supports general sensitivity context; it does not validate this sample signal.
The sample is assigned a lactase-persistence-associated pattern. This concerns one pathway of lactose digestion; it does not diagnose tolerance, allergy or the cause of digestive symptoms.
Next questionIf I have symptoms after dairy, what evaluation would be appropriate?
Established associationEvidence & limits
Variant interpretation depends on the particular marker and population. This sample provides no genotype or diagnostic result. Secondary lactose intolerance can have other causes.
The demonstration profile leans toward a later sleep preference. It is a prompt to look at real sleep timing, work demands and daylight exposure.
Next questionWhat does a two-week sleep record say about the schedule that works for me?
Exploratory associationEvidence & limits
No polygenic model was run. This assigned tendency does not determine a bedtime, required sleep duration or a diagnosis. The source supports healthy routines rather than this synthetic prediction.
DNA does not provide a current vitamin D blood level. This sample deliberately leaves nutrient status unassigned rather than turning a genetic tendency into a supplement instruction.
Next questionIs there a clinical reason to assess my vitamin D status?
Clinical measurement neededEvidence & limits
A blood test measures vitamin D status. Whether testing or supplementation is appropriate depends on clinical context; no dose or laboratory result is supplied here.
The fictional profile contains a mixed set of exercise-trait signals. It receives no “best sport,” injury forecast or training prescription. Current capacity and response remain the useful measures.
Next questionWhat do my training history, recovery and goals suggest I should change?
Limited practical utilityEvidence & limits
Sports-genetics associations are not a reliable basis for talent selection or individualized training. This sample uses no real performance model or genetic markers.
The sample does not turn a chronotype tendency into an exact eating window. Meal timing needs to fit health, medication requirements, activity and daily life.
Next questionWould a dietitian see a reason to change my current meal pattern?
Insufficient for prescriptionEvidence & limits
No validated meal-timing algorithm is applied. Discuss meaningful dietary changes with a qualified professional; this is not a fasting or nutrition prescription.
Separate uncertain findings, technical gaps, limited negative results and models that were not applied.
H01
Interpretation / SIM-V204
Variant of uncertain significance
Synthetic finding SIM-V204 remains unresolved. Its relevance to health is unknown. It is shown because uncertainty deserves a visible place in a report.
Next questionWould my symptoms or family history justify a clinical genetics review independently of this VUS?
Uncertain significanceEvidence & limits
SIM-V204 is an invented identifier, not a real variant. A VUS cannot establish a diagnosis. It should not drive a treatment or screening change on its own.
The synthetic region SIM-R12 is not confidently resolved. It is explicitly marked as a gap, even though the example genome-wide average depth is 31.8×.
Next questionIs this region relevant to the reason for testing, and would another method be useful?
Technical limitationEvidence & limits
SIM-R12 is not a genomic coordinate or gene. Average depth can hide uneven coverage; an unobserved or unresolved region is not a negative finding.
The invented screening summary contains no reportable finding within its demonstration scope. This is a limited result, not an “all clear” for future disease.
Next questionHow should routine care and family-history-based screening continue?
Scope-limited findingEvidence & limits
No actual clinical panel was analyzed. Real negative results depend on what was assessed and what the method can detect; missed or unknown causes remain possible.
Review the simulated diplotype, its gene–drug-specific evidence, and the clinical information still needed.
M01
CYP2C19 / PPI context
*17/*17 · ultrarapid metabolizer
The simulated diplotype corresponds to an ultrarapid CYP2C19 metabolizer phenotype. CPIC discusses reduced exposure to selected proton pump inhibitors and possible treatment failure.
Next questionIf a PPI is relevant to my care, would a confirmed result change the choice, monitoring or prescribing plan?
Fictional call; not clinically confirmed. The PPI recommendation for ultrarapid metabolizers is rated optional in the cited guideline. This does not apply equally to all drugs or PPIs. No dose advice is provided.
Inspect the fictional regional mix and compare direct lineage methods with autosomal ancestry.
A01
Reference affinity / model A
46% / 34% / 20%
The invented mix is Northwest European 46%, South Asian 34% and West African 20%. These numbers exist solely to demonstrate how an ancestry workspace could look.
Next questionWhich reference populations, model version and confidence ranges would accompany a real estimate?
Statistical estimateEvidence & limits
No DNA or reference algorithm was used. Real estimates vary with databases and methods. Percentages are not nationality, identity or proof of a specific ancestor.
No mitochondrial or Y-chromosome haplogroup has been assigned in this fictional report. An autosomal mixture cannot substitute for a lineage-specific analysis.
Next questionWould lineage testing answer the genealogical question I actually have?
Not assessedEvidence & limits
A lineage describes one ancestral path, not the complete family tree. The sample does not infer chromosome complement, sex or family relationships.
The illustrative map shows reference regions without a migration route or a date. A geographic affinity should not be turned into a precise family story without supporting evidence.
Next questionWhich records or tested relatives could help investigate our family history?
Insufficient informationEvidence & limits
Historical population movement complicates interpretation. This fictional estimate cannot identify an individual ancestor, a border crossing or a generation.
All regions, percentages and branch identifiers below are fictional.
Fictional reference affinityMap is not a migration route
Northwest European · 46% assigned in this fictional example. A broad reference label, not a country, ethnicity, identity or proof of a named ancestor.
Lineage model / fictional branches
Maternal and paternal lineage methods
These DEMO identifiers illustrate two inheritance paths. They are not haplogroups, genetic calls or relatives. Sample 001’s lineage status remains not assessed.
A direct maternal path
DEMO-M0Maternal grandmother
DEMO-M1Mother
DEMO-M2Teaching subject
Mitochondrial DNA is generally inherited through the egg cell. Children can inherit it; transmission onward follows the maternal line.
This follows one direct maternal chain, not all of a person’s maternal ancestry. The subject’s capacity to pass it onward is not inferred here.
A conditional paternal path
DEMO-Y0Paternal grandfather
DEMO-Y1Father
DEMO-Y2Teaching subject
Y-chromosome testing can follow a direct paternal line when suitable Y data exists. This diagram assumes a hypothetical Y dataset; no such data was assessed for Sample 001.
A Y lineage represents one paternal chain, not all paternal ancestry. It does not establish the subject’s chromosomes, sex, gender or family relationships.
Maternal teaching route selected: DEMO-M0, maternal grandmother; DEMO-M1, mother; DEMO-M2, teaching subject. All other branches are omitted.
Autosomal ancestry uses a different method. Autosomal estimates compare signals across many ancestral lines. The fictional 46% / 34% / 20% mix cannot be assigned to these DEMO branches.
Geography and dates are not inferred. No geographic origin, ancestral age, haplogroup or migration route is assigned by this teaching tree.
Read the baseline carrier scenario, then explore the simplified model. Unknown genotypes leave the probabilities blank.
F01
Carrier model / parent A
Aa · fictional carrier
Parent A is assigned Aa in a simplified autosomal recessive model. The other reproductive parent is initially untested, so this report does not calculate an affected-child probability.
Next questionWould clinical carrier screening for the same condition be appropriate for both reproductive parents?
Established inheritance modelEvidence & limits
A/a are teaching symbols, not a named gene or real genotype. Recessive inheritance is condition-specific; a carrier result needs appropriate interpretation.
The interactive model only calculates when both genotypes are explicitly selected. Selecting “Untested” clears all percentages rather than assuming the other person is not a carrier.
Next questionWhat can and cannot be learned from one person’s carrier screen alone?
Information incompleteEvidence & limits
The interactive model is a classroom calculation, not a couple’s risk estimate. Each pregnancy is a separate event; the model makes simplified assumptions.
Even an informative carrier screen cannot rule out every possible inherited condition or variant. A real result needs test scope, detection limitations and family context.
Next questionWhat residual risk remains after the particular tests we are considering?
Detection-limited resultEvidence & limits
The calculator’s AA option means a known model genotype. It must not be confused with a real negative carrier screen, which can miss variants.
A teaching model for one condition. It does not estimate a real couple’s reproductive risk.
A teaching model · no personal results
Compare two known model genotypes
—
aa / model affected
—
Aa / model carrier
—
AA / model non-carrier
Parent B is untested. Probabilities are withheld; an unknown genotype is not the same as AA.
Assumptions: one autosomal recessive condition, known correct genotypes, a fully penetrant aa model, no new variants or other inheritance mechanisms. Each pregnancy is independent. AA here is not equivalent to a real negative carrier screen. This is not a reproductive risk calculator.
Genome & files
FICTIONAL DATA
Inspect synthetic quality, the file catalogue and the recorded interpretation change.
G01
Sequencing / illustrative quality
31.8× average depth
The example manifest records 31.8× average depth. This is an invented laboratory-style metric, not evidence of a completed sequence or the quality of the proposed service.
Next questionWhat breadth of coverage and region-specific limitations would the laboratory provide?
Synthetic quality metricEvidence & limits
Depth is an average, not uniform completeness or a guarantee of variant detection. The proposed service targets 30× average; no real sample QC exists in this preview.
The manifest names the kinds of files a genomic handover might include. Filenames are invented; file sizes and checksums are omitted. No raw genome files exist behind these rows.
Next questionWhich deliverables, reference build and pipeline versions are included in the live service?
Format guideEvidence & limits
FASTQ holds reads and quality scores; aligned reads and called variants are processed products. Formats and analysis metadata matter when considering reanalysis.
The fictional report preserves a previous interpretation beside a newer edition. The underlying sequence stays the same in this example; the meaning assigned to one finding changes.
Next questionWill a real update show the reason, evidence date and practical implications of a change?
Illustrative change logEvidence & limits
These editions and review events are invented. No monitoring, expert review or notification service has taken place for this sample.
Synthetic finding SIM-V102 moves from uncertain significance in v1.1 to likely benign in v1.2. The sample illustrates an update that reduces concern instead of adding another warning.
Next questionWhat evidence changed, and does the new classification affect any previous clinical discussion?
Illustrative reclassificationEvidence & limits
SIM-V102 is not a real variant. Reclassification can occur as evidence develops; an actual update must be tied to a particular laboratory finding and current clinical context.
Synthetic manifest · invented filenames, no genomic files, fabricated gigabyte sizes or download buttons. A real delivery would identify the reference genome, pipeline, file integrity and quality metrics.
v1.1 / fictional earlier edition
Uncertain significance
SIM-V102 Insufficient evidence for classification. No care change from this finding alone.
v1.2 / fictional current edition
Likely benign
SIM-V102 Newly simulated evidence lowers concern. No disease prediction from this finding.
What changed: an invented evidence review, not the DNA. This is a demonstration of transparent reclassification; no real variant or monitoring event is represented.
Proposed lifetime interpretation updates mean updates for the lifetime of the Whole DNA service, within its supported analysis scope. New sequencing, laboratory assays and clinical appointments are separate. Final cadence, retention and exit arrangements must be confirmed before ordering opens.